Menarini introduces multiple myeloma assay

By The Science Advisory Board staff writers

April 1, 2021 -- Menarini Silicon Biosystems has launched the CellSearch Circulating Multiple Myeloma Cells (CMMCs) Assay. The new assay will assist pharmaceutical companies, contract research organizations, clinicians, and research scientists working on multiple myeloma.

The new assay captures and enumerates CMMCs from peripheral blood. It has the potential to reduce bone marrow biopsies with a noninvasive method to monitor multiple myeloma evolution and study disease biology.

CMMCs are increased in the peripheral blood of multiple myeloma patients and in patients with two precursor diseases: monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM). Because there is a high degree of correlation between Cellsearch CMMC counts and disease burden, the assay has the potential to offer a standardized method to monitor disease status in clinical trials, the firm said.

Menarini Silicon launches CellMag product line
Menarini Silicon Biosystems has launched its CellMag product line for the manual enrichment and staining of rare circulating tumor cells.
Menarini Silicon upgrading 2 systems
Menarini Silicon Biosystems has announced the company will upgrade its CellSearch and DEPArray systems to help advance clinical research into liquid biopsy.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter